Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers

Forthcoming EU call topic HORIZON-MISS-2027-02-CANCER-02 · HORIZON Innovation Actions. Part of call HORIZON-MISS-2027-02: Supporting the implementation of the Cancer Mission. Opens 2027-02-10; next deadline 2027-09-16. Topic page: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-02

Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: - Patients afflicted by lung, bowel, breast or prostate cancer[1], will benefit from the outcomes of evidence-based, tailored, innovative, affordable and accessible diagnosis- and treatment-centred clinical research programmes by comprehensive cancer infrastructures[2]. - Researchers, physicians, patient representatives, civil society, charities, foundations, insurance companies, SMEs and innovators[3] will seize opportunities to respectively co-create, support, upscale or commercialise outcomes of evidence-based, tailored, affordable and accessible clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer. - National and regional healthcare providers, healthcare payers, policymakers and authorities in European regions, EU Member States and Associated Countries have the evidence to engage in piloting, upscaling or implementing appropriate clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer.

Scope: Lung, bowel, breast and prostate cancer incidence, mortality and prevalence across EU Member States and Associated Countries are increasing while showing substantial variation, with Central and Eastern European communities, regions and countries particularly affected[4]. At the same time, the level of development of comprehensive cancer infrastructures continues to vary considerably across EU Member States…